CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. RESEARCH METHODOLOGY
1.3.1. Secondary research
1.3.2. Primary research
1.3.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.2.3. Top winning strategies
3.3. PORTER’S FIVE FORCES ANALYSIS
3.4. MARKET SHARE ANALYSIS, 2017

CHAPTER 4 LIVER-ON-CHIP MARKET, BY APPLICATION

4.1. OVERVIEW
4.2. DRUG DISCOVERY
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size & forecast
4.3. TOXICOLOGY RESEARCH
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size & forecast
4.4. DISEASE MODEL DEVELOPMENT  
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size & forecast

CHAPTER 5 LIVER-ON-CHIP MARKET, BY GEOGRAPHY

5.1. OVERVIEW
5.2. NORTH AMERICA
5.2.1. Key market trends
5.2.2. Growth factors and opportunities
5.2.3. Market size & forecast, by application
5.2.4. Market size & forecast, by country
5.2.5. U.S.
5.2.6. Canada
5.2.7. Mexico
5.3. EUROPE
5.3.1. Key market trends
5.3.2. Growth factors and opportunities
5.3.3. Market size & forecast, by application
5.3.4. Market size & forecast, by country
5.3.5. UK
5.3.6. Germany
5.3.7. France
5.3.8. Rest of Europe
5.4. ASIA-PACIFIC
5.4.1. Key market trends
5.4.2. Growth factors and opportunities
5.3.3. Market size & forecast, by application
5.2.4. Market size & forecast, by country
5.4.5. China
5.4.6. Japan
5.4.7. India
5.4.8. Australia
5.4.9. Rest of Asia-Pacific
5.5. LAMEA
5.5.1. Key market trends
5.5.2. Growth factors and opportunities
5.5.3. Market size & forecast, by application
5.5.4. Market size & forecast, by sub-region
5.5.5. Latin America
5.5.6. Middle East
5.5.7. Africa

CHAPTER 6 COMPANY PROFILES

6.1. AXOSIM TECHNOLOGIES LLC  
6.1.1. Company overview
6.1.2. Operating business segments
6.1.3. Product portfolio
6.1.4. Business performance
6.1.5. Key strategic moves and developments
6.2. CN INNOVATIONS HOLDINGS LIMITED (CN BIO INNOVATIONS)
6.2.1. Company overview
6.2.2. Operating business segments
6.2.3. Product portfolio
6.2.4. Business performance
6.2.5. Key strategic moves and developments
6.3. EMULATE, INC.
6.3.1. Company overview
6.3.2. Operating business segments
6.3.3. Product portfolio
6.3.4. Business performance 6.3.5. Key strategic moves and developments
6.4. ASCENDANCE BIOTECHNOLOGY, INC. 6.4.1. Company overview
6.4.2. Operating business segments
6.4.3. Product portfolio
6.4.4. Business performance
6.4.5. Key strategic moves and developments
6.5. HUREL CORPORATION
6.5.1. Company overview
6.5.2. Operating business segments
6.5.3. Product portfolio
6.5.4. Business performance
6.5.5. Key strategic moves and developments
6.6. INSPHERO AG
6.6.1. Company overview
6.6.2. Operating business segments
6.6.3. Product portfolio
6.6.4. Business performance 6.6.5. Key strategic moves and developments
6.7. MIMETAS B.V.
6.7.1. Company overview
6.7.2. Operating business segments
6.7.3. Product portfolio
6.7.4. Business performance 6.7.5. Key strategic moves and developments
6.8. NORTIS INC.
6.8.1. Company overview
6.8.2. Operating business segments
6.8.3. Product portfolio
6.8.4. Business performance
6.8.5. Key strategic moves and developments
6.9. ORGANOVO HOLDINGS, INC.
6.9.1. Company overview
6.9.2. Operating business segments
6.9.3. Product portfolio
6.9.4. Business performance
6.9.5. Key strategic moves and developments
6.10. TARA BIOSYSTEMS, INC.
6.10.1. Company overview
6.10.2. Operating business segments
6.10.3. Product portfolio
6.10.4. Business performance
6.10.5. Key strategic moves and developments